Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Phase 3
Completed
- Conditions
- Chronic Kidney DiseaseChronic Allograft NephropathyHyperparathyroidismKidney DiseasePost Renal TransplantationKidney TransplantationChronic Renal FailureHypophosphatemiaDisordered Mineral MetabolismEnd Stage Renal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 114
- Registration Number
- NCT00975000
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
Phase 3
Completed
- Conditions
- HypercalcemiaHyperparathyroidism, Primary
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT00975221
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
AMG 745 in Subjects With Age-associated Muscle Loss
Phase 2
Withdrawn
- Conditions
- Age-associated Muscle Loss
- Interventions
- Drug: AMG 745 1.0 mg/kgDrug: PlaceboDrug: AMG 745 3.0 mg/kgDrug: AMG 745 0.3 mg/kg
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00975104
Safety Study of Tezepelumab (AMG 157) in Healthy Adults
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 49
- Registration Number
- NCT00972179
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT00950950
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Phase 3
Completed
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT00950911
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT00950989
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 17
- Registration Number
- NCT00947544
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸The George Washington DC Children's National Medical Center, Washington, District of Columbia, United States
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT00947297
- Locations
- 🇺🇸
SNBL-Clinical Pharmacology Center, Baltimore, Maryland, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 78
- Registration Number
- NCT00936650
© Copyright 2025. All Rights Reserved by MedPath